YIM Oral Poster

1018 - Unraveling the NOTCH1/MSI2/c-MYC Signaling Pathway Reveals a Novel Vulnerability in Chronic Lymphocytic Leukemia Progression

1019 - Immunological Landscape of CLL Development and Response to Early BTK Inhibition in del(13q14) Mice

1020 - KRAS^G13D-Dependent PI3K/AKT Signaling Regulates Fatty Acid Oxidation in Chronic Lymphocytic Leukemia

1021 - Normal B Cells in MBL Show Abnormal Transcriptomic and Subset Distributions Compared to Healthy Donors: Evidence for Follicular Maturation in IGHV-Mutated MBL and Extrafollicular Maturation in IGHV-Unmutated MBL

1102 - Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania.

1119 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

1120 - Serum LC-MS based untargeted metabolomics machine learning for distinguishing asymptomatic and symptomatic CLL/SLL and predicting TTFT

1204 - EGR2 Hotspot Mutations Drive BTKi Resistance in Chronic Lymphocytic Leukemia via CD27-CD70 Interaction-Mediated T-Cell Exhaustion

1205 - Investigating the eEF2K/eEF2 axis as a potential target in CLL following nelfinavir treatment

1206 - Subversion of ERK-MAPK-mediated mRNA translation elongation as a therapeutic strategy in CLL

1210 - Imaging mass cytometry reveals distinct cellular architectures in proliferative and non-proliferative regions of the chronic lymphocytic leukaemia lymph node tumour microenvironment

1303 - Targeting Lysosomes in the Chronic Lymphocytic Leukemia Microenvironment

1439 - Ten-year follow-up of a phase II study of ibrutinib in relapsed/ refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)

1501 - EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL-WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP

1701 - Development and evaluation of a selection-algorithm optimised ensemble model for predicting infection risk in CLL using structured and unstructured electronic patient record data